



# MARYLAND TECH COUNCIL

June 30, 2023

Sent via Email: [comments.pdab@maryland.gov](mailto:comments.pdab@maryland.gov)

Maryland Prescription Affordability Board  
16900 Science Drive  
Suite 112-114  
Bowie, MD 20715

**RE:** Revised Draft Regulations

On behalf of the Maryland Tech Council (the “Tech Council”), thank you for the opportunity to provide comments on the revised draft regulations proposed by the Prescription Drug Affordability Board (the “PDAB” or “Board”). The Tech Council appreciates that the revisions to the draft regulations reflect many of the critical changes requested by stakeholders to the initial draft. As stated in our preliminary comments, the Tech Council is the State’s largest association of technology companies with over 700 member companies across multiple technology sectors including life sciences, biotechnology, and others. The Council’s vision is to propel Maryland to become the number one innovation economy for life sciences and technology in the country.

As the PDAB considers stakeholder comments to the revised draft regulations and finalizes the regulatory framework that will be officially published for public comment, the Tech Council wishes to reiterate its request that PDAB consider the potential impacts the regulations will have on the environment for innovation and competitiveness for life sciences and biotech in Maryland. Despite being one of the leading states in the nation for the concentration of life sciences companies and jobs, Maryland continues to be challenged by other states who have prioritized making strategic and significant investments to expand and enhance the life sciences industry. As noted in our initial comments, companies must consider the regulatory environment when determining whether to locate or expand.

The Tech Council urges PDAB to carefully consider the comments submitted to these revised draft regulations by the biotechnology and life sciences industry, such as the Biotechnology Innovation Organization (BIO), and adopt any additional amendments necessary to protect the State’s ability to remain a national leader in life sciences and biotechnology. The adoption of a regulatory framework that does not incorporate the industry’s concerns could dramatically impact the State’s ability to not only recruit new companies and expand job opportunities but also retain its current status as a national leader committed to growing its innovation economy.

Thank you for the opportunity to comment on the revised draft regulations prior to their formal publication for public comment. We look forward to continuing to work productively with the Board as it continues its work to ensure that prescription drugs are affordable and accessible to Marylanders. Please do not hesitate to contact me at [kelly@mdtechcouncil.com](mailto:kelly@mdtechcouncil.com) or (240) 243-4026 to discuss these matters in greater detail.

Sincerely,

Kelly Schulz, CEO  
Maryland Tech Council